American Century Companies Inc., a prominent institutional investor, recently increased its holdings in Establishment Labs Holdings Inc. During the first quarter, American Century Companies purchased an additional 4,854 shares of Establishment Labs stock, which represents a 1.9% increase in their overall holdings. As of their most recent filing with the Securities and Exchange Commission (SEC), American Century Companies now owns a total of 258,614 shares of Establishment Labs stock, valued at approximately $17,487,000.
Establishment Labs Holdings Inc. is a leading medical technology company that specializes in the manufacturing and marketing of medical devices used in aesthetic and reconstructive plastic surgery. The company’s flagship product is the Motiva Implants brand of silicone gel-filled breast implants. These implants have gained significant recognition within the industry for their high quality and innovative design.
In addition to Motiva Implants, Establishment Labs also offers other breast implant options such as Motiva Ergonomix and Motiva Ergonomix2 gravity-sensitive round soft silicone-gel-filled implants. These unique implants are designed to provide a more natural feel and appearance to patients undergoing breast augmentation or reconstruction procedures.
Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander, which is utilized as a breast tissue expander during reconstructive surgeries. This device allows for gradual expansion of the breast tissue over time until it reaches the desired volume.
The increase in American Century Companies’ holdings suggests a growing confidence in Establishment Labs’ potential for future growth and success within the medical technology industry. This noteworthy investment by an institutional investor of such caliber can often be seen as a positive sign for other investors considering entering or expanding their positions in Establishment Labs.
It is important to note that this information is based on American Century Companies’ disclosure with the SEC, which provides valuable insight into their investment strategy. However, it should not be taken as financial advice or a guarantee of future performance for Establishment Labs or its stock. Investors are encouraged to conduct their own research and consult with financial advisors before making any investment decisions.
In conclusion, American Century Companies Inc. has increased its holdings in Establishment Labs Holdings Inc., a recognized leader in the medical technology industry. As a manufacturer and marketer of top-quality breast implants and tissue expanders, Establishment Labs continues to drive innovation in aesthetic and reconstructive plastic surgery. This investment by American Century Companies highlights their confidence in the company’s potential for growth and success moving forward.
[bs_slider_forecast ticker=”ESTA”]
Hedge Funds Show Interest in Establishment Labs as Analysts Remain Bullish
In recent news, various hedge funds have made significant changes to their positions in Establishment Labs (NASDAQ: ESTA), a leading medical technology company specializing in breast implants and aesthetic surgery products. Notably, Citigroup Inc. witnessed a remarkable increase of 221.1% in its holdings of shares from the first quarter, amounting to 1,554 shares valued at $105,000. Similarly, Credit Suisse AG also saw a rise of 5.7% in their ownership of Establishment Labs’ shares during the same period, now holding 22,682 shares valued at $1.54 million.
Additionally, Bessemer Group Inc., recognized for its notable investment strategies, acquired a new position in the company’s stock valued at approximately $132,000 during the first quarter. Kornitzer Capital Management Inc. KS increased its hold on Establishment Labs by 0.3% from the previous quarter, currently possessing 304,380 shares worth $20.62 million.
Cowen AND Company LLC displayed growth of 1.1% in its holdings of Establishment Labs during the first quarter as well, owning 866,172 shares worth $58.67 million after acquiring an additional 9,518 shares.
It is noteworthy that institutional investors and hedge funds currently own around 71.6% of the total stock distributed by Establishment Labs.
Given these developments within the investor landscape related to Establishment Labs’ stock performance recently analyzed by hedge funds and market analysts alike seems promising and has garnered attention among several reputable firms.
Citigroup began coverage on Establishment Labs with a “buy” rating alongside a price objective of $79 per share back on June 29th.
JPMorgan Chase & Co., another prominent financial institution providing investment insights initiated coverage on September this year assessing Establishment Lab’s performance positively with an “overweight” rating accompanied by a target price of $75.
Stephens also reiterated an “overweight” rating and issued a price objective of $89 on July 21st.
Currently, according to Bloomberg, five investment analysts have given the stock a “buy” rating. Notably, the consensus target price for Establishment Labs stands at $91.6.
On Friday, NASDAQ ESTA opened at $60.37, with a fifty-day moving average of $63.86 and a 200-day moving average of $67.46. The company has demonstrated strong financial health with its market capitalization hovering around $1.56 billion.
However, it is worth noting that Establishment Labs carries a high debt-to-equity ratio of 3.32 as well as negative net margins of approximately 34.35% and negative return on equity reaching 755.73%. These financial indicators pose potential risks for investors to consider before engaging in buy or sell decisions regarding the company’s shares.
Looking forward, analysts predict that Establishment Labs Holdings Inc.’s earnings per share (EPS) for the current year will be around -2.48 based on their evaluation of the company’s recent quarterly earnings report released on August 8th.
Establishment Labs remains poised to continuously provide innovative medical technologies within the aesthetic surgery industry, despite facing some financial challenges reflected in its performance metrics over recent years. Investors should keep an eye out for upcoming developments and regulatory changes that may affect the company’s operations and market position in the future.